AMSTERDAM, June 28, 2017 /PRNewswire/ --
Launch date set for first quarter 2018
Norgine B.V. today announced that it has received acceptance from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) for PLENVU(R)* (NER1006). PLENVU(R) is a novel, low-volume (1L) polyethylene glycol based bowel preparation that has been developed to provide complete bowel cleansing, with an additional focus on the ascending colon.
In August 2016, Norgine out-licensed PLENVU(R) to Salix in the US and Canada.
Peter Stein, Chief Executive Officer, Norgine, said "We are pleased to receive filing acceptance from the FDA for PLENVU(R) and we are looking forward to continuing our collaboration with Salix. This partnership will ensure that patients have access to a new and proven low volume bowel preparation that can improve the quality of colonoscopy. In turn this will ultimately enhance the detection of adenomas and polyps that frequently go undetected and often result in colorectal cancer."
"Effective bowel preparation is an important factor for a successful colonoscopy and for detecting adenomas and polyps," said Mark McKenna, senior vice president and general manager, Salix Pharmaceuticals. "If approved, PLENVU(R) may enhance bowel cleansing and the overall bowel prep experience relating to a colonoscopy."
Norgine will manufacture PLENVU(R) globally and commercialise the product through its infrastructure in Europe, Australia and New Zealand.
*Provisionally approved name
View the full release on http://www.norgine.com
Norgine Media Contacts
T: +44 (0)1895 453643
T: +44 (0)1895 453607
Follow us @norgine [https://twitter.com/norgine ]